Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Subcutaneous secukinumab prevents radiographic progression in psoriatic arthritis

10 Apr 2018

Treatment with subcutaneous secukinumab leads to significant inhibition of radiographic progression and improvement of clinical signs and symptoms in patients with psoriatic arthritis (PsA), according to the results of the FUTURE 5 study.

The phase III study randomly assigned 996 adult patients (mean age 48.8 years; 49.8 percent female; mean time since PsA diagnosis, 6.6 years) to the following treatment arms: secukinumab 300 mg with loading dose (LD; n=222), secukinumab 150 mg with LD (n=220), secukinumab 150 mg without LD (n=222) or placebo (n=332). Treatment was administered at baseline, weeks 1, 2 and 3, and then every 4 weeks from week 4.

At week 16, the primary endpoint of the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response was significantly greater in all secukinumab arms than in the placebo arm (62.6 percent in the 300-mg group, 55.5 percent in the 150 mg with LD group and 59.5 percent in the 150 mg without LD group vs 27.4 percent; p<0.0001 for all).

At week 24, radiographic progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited in all secukinumab arms vs placebo arm (p<0.01 for 300 mg with LD and 150 mg without LD; p<0.05 for 150 mg with LD).

Adverse event rates at week 24 were comparable across treatment arms: 63.1 percent for 300 mg with LD, 62.7 percent for 150 mg with LD, 61.1 percent for 150 mg without LD, and 62.0 percent for placebo. There were no reports of deaths or new safety signals.

FUTURE 5 demonstrates the efficacy of subcutaneous secukinumab 300 mg and 150 mg, as well as the benefit of an LD regimen (regardless of the dose) especially when aiming for higher levels of response and faster outcomes in joint and skin endpoints, in the treatment of PsA, researchers said.

Moreover, the present data confirm and extend the results of previous studies demonstrating the therapeutic potential of secukinumab in achieving comprehensive treatment goals in PsA, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.